Predictors of growth patterns in children with mucopolysaccharidosis I after haematopoietic stem cell transplantation

Stefanie Maier¹ | Miroslav Zivicnjak² | Lorenz Grigull³ | Julia B. Hennermann⁴ | Charlotte Aries⁵ | Britta Meecker-Kolhoff¹ | Martin Sauer¹ | Anibh M. Das² | Rita Beier¹

¹Department of Paediatric Haematology and Oncology, Hannover Medical School, Hannover, Germany
²Department of Paediatric Kidney, Liver and Metabolic Diseases at Hannover Medical School, Hannover, Germany
³Rare Disease Centre, Bonn University Medical Centre, Bonn, Germany
⁴Villa Metabolica, Department of Paediatric and Adolescent Medicine, University Medical Centre Mainz, Germany
⁵Department of Paediatrics, Hamburg-Eppendorf University Medical Centre, Hamburg, Germany

Correspondence
Rita Beier, Department of Paediatric Haematology and Oncology at Hannover Medical School Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Email: beier.rita@mh-hannover.de

Funding information
Hannover Medical School

Communicating Editor: Roberto Giugliani

Abstract
Mucopolysaccharidosis type I (MPS I) is an autosomal-recessive metabolic disorder caused by an enzyme deficiency of lysosomal alpha-L-iduronidase (IDUA). Haematopoietic stem cell transplantation (HSCT) is the therapeutic option of choice in MPS I patients younger than 2.5 years, which has a positive impact on neurocognitive development. However, impaired growth remains a problem. In this monocentric study, 14 patients with MPS I (mean age 1.72 years, range 0.81–3.08) were monitored according to a standardised follow-up program after successful allogeneic HSCT. A detailed anthropometric program was carried out to identify growth patterns and to determine predictors of growth in these children. All patients are alive and in outpatient care (mean follow-up 8.1 years, range 0.1–16.0). Progressively lower standard deviation scores (SDS) were observed for body length (mean SDS −1.61; −4.58 – 3.29), weight (−0.56; −3.19 – 2.95), sitting height (−3.28; −7.37 – 0.26), leg length (−1.64; −3.88 – 1.49) and head circumference (0.91; −2.52 – 6.09). Already at the age of 24 months, significant disproportions were detected being associated with increasing deterioration in growth for age. Younger age at HSCT, lower counts for haemoglobin and platelets, lower potassium, higher donor-derived chimerism, higher counts for leukocytes and recruitment of a matched unrelated donor (MUD) positively correlated with body length ($p \leq 0.05$). In conclusion, this study characterised predictors and aspects of growth patterns in children with MPS I after HSCT, underlining that early HSCT of MUD is essential for slowing body disproportion.

KEYWORDS
anthropometry, children, growth pattern, haematopoietic stem cell transplantation, mucopolysaccharidosis I

This study received funding by the Department of Paediatric Kidney, Liver and Metabolic Diseases at Hannover Medical School, Hannover, Germany.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.
1 | INTRODUCTION

Type I mucopolysaccharidosis (MPS I) is an autosomal-recessive metabolic disorder caused by an enzyme deficiency in lysosomal alpha-L-iduronidase (IDUA), which leads to accumulation of glycosaminoglycans (GAGs). Based on severity of symptoms, three clinical phenotypes are distinguished: severe Hurler, intermediate Hurler-Scheie and attenuated Scheie syndrome. The clinical manifestation includes hydrocephalus, cardiac disease, airway compromise, hepatosplenomegaly, psychomotor delay and hearing loss.1,2 Musculoskeletal involvement is characterised by abnormal growth, dysostosis multiplex, severe skeletal deformities and degenerative joint disease.3 Therapeutic options to modify disease in MPS I include haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) with recombinant alpha-iduronidase. As ERT does not cross the blood–brain barrier, it does not sufficiently stabilise cognitive or central nervous system function.4 Early diagnosis and HSCT at young age are the appropriate treatment.5,6 It is the only therapy that allows long-term survival and prevents or delays complications including neuropsychological impairment.7,8 Skeletal deformities, however, are not amenable to HSCT and continue to progress.9 MPS I leads to impaired growth and development.10 The disease may cause a sequence of pathological processes, which promote inflammation, cartilage degradation and hyperplasia of synovial membranes resulting in poorly organised and metabolically abnormal connective tissue matrices.11 In future, for children with MPS I gene therapy might be an option.12

Monitoring growth parameters of these children is critical in assessment of disease progression and therapeutic success. Nevertheless, the body of data on factors that impact growth patterns after HSCT in these children are limited. Only head circumference and body length have traditionally been measured.13 The objective of this study was to execute a detailed program capturing growth patterns of patients with MPS I after HSCT and define predictors of growth.

2 | METHODS

2.1 | Patients

This was a mono-centric, prospective, longitudinal, non-randomised study. Fourteen patients (eight female, six male) with MPS I underwent HSCT at Hannover Medical School between 2001 and 2018. Mean age at HSCT was 1.72 years (range 0.81–3.08). Diagnosis was confirmed by clinical picture and enzyme deficiency and/or genetic analysis. If age at diagnosis was >2 years, paediatric neurologists and HSCT team discussed proceeding to HSCT with the parents after neurocognitive evaluation. Characteristics of included patients, detailed information about HSCT and a description of the orthopaedic pathologies are summarised in additional material (Tables S1–S3). Patient 13 received a second HSCT because of graft failure after HSCT; there we used second HSCT for further analysis. Patients were transplanted using the MPS-HCT 2005 preparative regime.14,15

2.2 | Data collection

In addition to standard HSCT follow-up procedures, a detailed anthropometric program was implemented, which was in accordance with standardised technique as recommended by the ‘International Biological Program’.16 Body length, sitting height, leg length, head circumference and body weight were recorded and compared to age- and gender-specific reference data as standard deviation scores (SDS), which had been measured for 5155 healthy children aged 3–18 years.17 SDS for birth to 2 years were calculated from KiGGS 2003–2008.18

2.3 | Ethical considerations

The study was approved by the Ethics Committee of Hannover Medical School (#3701). Informed consent was obtained from patients and/ or their legal representative as appropriate.

2.4 | Statistical analysis

SDS values for the examined parameters were calculated according to the equation SDS = (xi – xs) /SD. Where xi represents the individual value of patient, xs and SD are the mean and SDS of the reference group, respectively. The normality of distribution was assessed for each age cohort and each observed parameter (Kolmogorov–Smirnov test). Data are presented as mean and 95%
confidence interval. All measurements were grouped according to age at examination. The linear-mixed effects models were used for the assessment of age and donor-related changes in linear growth of MPS I children after HSCT (mixed procedure in SPSS software, version 26). Statistical significance was assumed at $p \leq 0.05$. 

**FIGURE 1** Distribution of mean SDS relative to controls for weight, body length and head circumference in (A) the whole cohort, (B) cohort split by age at HSCT and (C) cohort split by donor type.
3 | RESULTS

3.1 | Patients

All patients who received HSCT for MPS I are alive and in outpatient care. The mean follow-up time was 8.1 years (range 0.1–16.05). Ten patients received HSCT from matched unrelated donor (MUD), while two patients were transplanted from matched sibling donors (patients 8 and 12) and two patients from haplo-identical donors (patients 4 and 7). Eight patients presented with full donor chimerism (donor cells ≥ 94%), while six patients exhibited

FIGURE 2  Distribution of mean SDS relative to control for body length, sitting height and leg length in (A) whole cohort, (B) cohort split by age at HSCT and (C) cohort split by donor type.
intermediate mixed chimerism (last chimerism in this cohort 85%–100%). Engraftment and GvHD data are shown (Table S4). Renal, thyroid function, growth hormone (GH) parameters, sexual hormones (measured in 7/14 patients), age at menarche and enzyme activity were normal in all patients (Table S5). No patient has received treatment for hypo- or hyperthyroidism, nor GH replacement.

3.2 | Infancy

At birth, body length, weight and head circumference were similar to the reference group. There is a further increase in head circumference SDS from 6 to 24 months, while body length and weight did not rise in this period. Relating growth development to age at HSCT, there is an increasing trend for disproportion in as yet untreated children at the age of 24 months, with increased weight and decreased length. At the same age, all parameters presented (Figure 1) recovered in transplanted patients.

Regarding the impact of donor type on growth development, growth was less disproportionate in patients receiving HSCT from a MUD than in those who were transplanted from a related donor (RD): this is particularly evident in greater SDS for head circumference SDS (Figure S1, Table S6).

3.3 | Age-related body proportions and growth

Figure 1 shows the mean SDS for weight, body length and head circumference from birth to the age of 12 years. Figure 2 presents age-related body dimensions (body length, sitting height and leg length) from 2 to 12 years of age (estimated marginal means in Table S7). In general, growth parameters in MPS patients decline over time and deterioration in linear growth manifests primarily in increasingly poor sitting height (mean SDS weight – 0.56 (range – 3.19 – 2.95), mean body length SDS – 1.61 (range – 4.58 – 3.29), mean SDS sitting height – 3.28 (range – 7.37 – 0.26), mean SDS leg length – 1.64 (range – 3.88 – 1.49)). Greater SDS for head circumference in infancy (mean SDS 0.91 [range – 2.52 – 6.09]) approached the reference group with increasing age.

Figures 1B and 2B show effects of age at HSCT: SDS values were worse, when patients were older than 2 years at HSCT. Age at HSCT has statistically significant effect on weight (p < 0.04), body length (p < 0.01) and sitting height (p < 0.03).

Figures 1C and 2C differentiate between donor types. Growth parameters fell with age in both groups to similar extent. There was a clear decrease in all parameters at the age of 4 years in children receiving HSCT from RD. Greater SDS for head circumference appeared especially for patients receiving HSCT of RD.

3.4 | Predictors of linear body dimensions

There was a significant positive correlation of younger age at HSCT, lower haemoglobin, lower platelet count, lower potassium, higher chimerism, higher leukocyte count and donor type with length SDS (p < 0.05, respectively), while enzyme activity of IDUA was not a significant predictor (Table 1). The sitting height index is the ratio between trunk length and total body height. A correlation between measured haemoglobin and current sitting height index (z-score) is attached (Figure S2). A tendency to normalisation of sitting height index was found when haemoglobin concentrations were lower.

| Covariate          | Estimate | SE  | 95% Confidence interval | p-value |
|--------------------|----------|-----|-------------------------|---------|
| Age at transplantation | −3.58 | 0.74 | −5.18 to −1.99           | <0.01   |
| Chimerism          | 0.10     | 0.04| 0.02 to 0.19             | 0.03    |
| Haemoglobin        | −0.99    | 0.23| −1.49 to −0.48           | <0.01   |
| Leukocytes         | 0.48     | 0.13| 0.21 to 0.75             | <0.01   |
| Platelets          | −0.01    | 0.00| −0.01 to 0.002            | 0.01    |
| Potassium          | −1.37    | 0.33| −0.64 to −2.10           | <0.01   |
| Enzyme activity    | 0.06     | 0.10| −0.15 to 0.27            | 0.50    |
| Type of donor      | 1.38     | 0.39| 0.55 to 2.21             | <0.01   |

Note: Data are presented as estimated marginal means (95% confidence intervals); p values are based on the linearly independent pairwise comparisons among the estimated marginal means.

*Measured at all follow-up, linear mixed-effects models include all measured values.

4 | DISCUSSION

This is the first study using standardised anthropometric procedures to measure a wide spectrum of growth
parameters in MPS I patients after HSCT. Before and soon after HSCT, growth pattern for MPS I showed the following: (1) children had a normal growth pattern at birth, (2) in comparison to the reference population, abnormal growth patterns were observed 4–6 months after birth (before HSCT), resulting in the significant disproportion of body dimensions at the end of infancy, (3) head circumference was above normal, especially for patients receiving HSCT of RD.

Some of these aspects were well known in children with MPS I after HSCT: Body length at birth was similar or increased compared to reference groups.19 One possible explanation for normal or increased growth in early life might be that heparan sulphate binds as co-receptor to proteins—including growth factors. Increased levels of heparan sulphate might overstimulate axial bone growth.20 An enlarged head circumference is a well-known feature of MPS I patients.21 Thickened calvaria, accumulation of GAGs and sphingolipids in neurons and neuroinflammation may be responsible for the phenotype.22 Kiely reported MPS I patients with an enlarged head circumference at median age of 8 months.23 Because of its early manifestation, higher-to-normal head circumference is often the key feature leading to diagnosis.13 This could be observed even slightly earlier in our cohort and underlines that the alteration in growth patterns begins considerably earlier than previously assumed.

Long-term follow-up in our study population gave new insights: (1) after initial stabilisation, longitudinal growth slowed down, (2) poor longitudinal body growth was associated with significant disproportion between sitting height and leg length, which resulted in disproportionate growth pattern for body length and (3) SDS values for body length were more favourable when MUD were available for HSCT, patients were younger at HSCT, achieved higher donor-derived haematopoietic chimerism, better leucocytes counts, lower counts for haemoglobin, platelets and lower serum potassium levels.

It was reported that median length falls below the third percentile in untreated MPS I patients.21 Although HSCT had positive impact on several key features and an initial period of catch-up growth is observed, it is followed by constant slowing down of growth in later childhood.24 There are variable signs of dysostosis multiplex and skeletal dysplasia despite of HSCT,9,25 which might have important effects on restricted linear growth. Genua valga, hip and spinal deformities may contribute to short leg length and sitting height and therefore lead to major reductions in body length. Sitting height and leg length were not separately addressed in previous studies.13,19,21 We found that the change in sitting height had the most prominent impact on compromised linear growth. This non-invasive parameter may be influenced by scoliosis and has less side effects than procedures employing X-ray. In transplanted patients before age of 2 years, we observed more normal SDS of all measured parameters, less disproportion and more harmonisation. Thus, early HSCT is not only essential to provide a possibility for improved neurologic development but also might have beneficial effect concerning the musculoskeletal involvement.

In our study, HSCT of MUD had positive impact on different length parameters, which might be due to higher secretion of IDUA. As in our study, we are reporting about long time frame of HSCT (2001–2018), donors were not pre-screened for enzyme activity, so there might even be heterozygous donors in the RD cohort, which is associated with poorer outcome in body length as already published.6

We confirmed that chimerism and age at HSCT influenced growth, but failed to find an effect of the underlying genotype or post-HSCT enzyme activity. Other studies reported an association of genotype and post-treatment IDUA with dysostosis multiplex,26 which contributed to shorter body length. This could be caused by GH deficiency, which is often diagnosed after HSCT.27 A treatment with GH might be discussed, but due to its long-term outcome is not fully described yet,28,29 it was not in our cohort. Long-term consequences of transplant conditioning to growth were also described.30,31 The latter factors may be related to degree of chimerism and donor type, which is in line with our data.32 Our small cohort might explain absence of a significant effect of enzyme activity on body length. As leucocytes of transplanted patients are the only site of production of IDUA, they may be significantly associated with length. Higher SDS values for length were associated with higher leucocyte levels. In addition to chimerism and leucocyte count, several predictors of linear body growth after HSCT were identified in this study: age at HSCT, haemoglobin, potassium, platelets and donor type.

Lower haemoglobin was associated with higher length SDS. A possible explanation for this phenomenon may be compromised respiratory function in severely affected patients with scoliosis which results in poor oxygenation and increased haemoglobin concentrations.33 Because of the deterioration in ventilation, respiratory acidosis may develop, with metabolic compensation.34 Potassium is an indirect parameter of renal regulation, and tends to compensate for respiratory acidosis. Therefore, lower potassium may be associated with higher length SDS due to the putative lower respiratory acidosis.

Lower platelet count correlated with higher length SDS. Arterial hypertension and stenosis are known in MPS I patients. Histopathological examination presented proliferation of collagen and elastic fibres and also not degradable mucopolysaccharides with markedly distended lysosomes.35 Thus, we suspect lower platelet count to prevent cardiovascular events. These aspects (haemoglobin,
potassium and platelets) should be examined in greater cohorts, to get more insight in the potential pathophysiology.

This study is limited by its small cohort with MPS I. Pulmonary function tests have not been conducted in all children due to poor compliance in small children. Pubertal status and bone age were not sufficiently evaluated. Unfortunately, we did not record the course of enzyme activity levels for all children after HSCT, which would be interesting even over time.

5 | CONCLUSION

This study characterised new predictors and aspects of growth patterns in children with MPS I after HSCT and underline the need for dedicated long-term follow-up. These patients presented a progressive imbalance in body proportions. Younger age at HSCT, lower haemoglobin, lower platelet count, lower potassium, higher chimerism, higher leukocyte count and donor type were significantly correlated with body length SDS.

Future studies are warranted to study these effects in greater cohorts and to provide more detailed analysis. This should increase our understanding of disease progression and therapeutic success in MPS I children.

ACKNOWLEDGMENTS

We are indebted to all patients and their families taking part in this study. We are grateful to Isolde Schridde and to the health care professionals of the paediatric stem cell transplantation inpatient and outpatient department of Hannover Medical School, without whom a successful HSCT would not have been possible. We also want to thank Prof. Dr. med. Christian Kratz and Prof. Dr. med. Dieter Haffner for their commitment. We wish to thank Dr. Rodney Yeates for editorial assistance. Open Access funding enabled and organized by Projekt DEAL.

CONFLICT OF INTEREST

All authors do not declare financial disclosures appropriate to have influence on the direction of the paper. RB received financial support for an advisory board by BluebirdBio regarding thalassemia patients, and congress travel costs by MEDAC and NEOVII.

ORCID

Rita Beier https://orcid.org/0000-0002-7568-8749

REFERENCES

1. Clarke LA, Giugliani R, Guffon N, et al. Genotype-phenotype relationships in mucopolysaccharidosis type I (MPS I): insights from the international MPS I registry. Clin Genet. 2019;96:281-289.
2. Beck M. Variable clinical presentation in lysosomal storage disorders. J Inherit Metab Dis. 2001;24:47-51.
3. White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology. 2011;50(5):26-33.
4. Shapiro EG, Eisengart JB. The natural history of neurocognition in MPS disorders: a review. Mol Genet Metab. 2021;133:8-34.
5. De Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.
6. Aldenhoven M, Wynn RF, Orchard PJ, et al. Long-term outcome of hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164-2172.
7. Aldenhoven M, Jones SA, Bonney D, et al. Hematopoietic cell transplantation for Mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21(6):1106-1109.
8. Taylor M, Khan S, Stapleton M, et al. Hematopoietic stem cell transplantation for Mucopolysaccharidases: past, present, and future. Biol Blood Marrow Transplant. 2019;25(7):e226-e246.
9. Field RE, Buchanan JAF, Copplemans MGD, Aichroth PM. Bone-marrow transplantation in Hurler’s syndrome. Effect on skeletal development. J Bone Jt Surg - Ser B. 1994;76(6):975-981.
10. Oussoren E, Brands MMMG, Ruijter JGJ, van der Ploeg AJT, Reuser AJJ. Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options. Biochim Biophys Acta - Mol Basis Dis. 2011;1812(11):1542-1556.
11. Simonaro CM, D’Angelo M, He X, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2008;172(1):112-122.
12. Gentner B, Tucci F, Galimberti S, et al. Hematopoietic stem-and progenitor-cell gene therapy for hurler syndrome. N Engl J Med. 2021;385:1929-1940.
13. Parini R, Jones SA, Harmatz PR, Giugliani R, Mendelsohn NJ. The natural history of growth in patients with hunter syndrome: data from the hunter outcome survey (HOS). Mol Genet Metab. 2016;117:438-446.
14. Grigull L, Beilken A, Schrappe M, et al. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. hurler). Bone Marrow Transplant. 2005;35(3):265-269.
15. Sauer M, Meissner B, Fuchs D, et al. Allogeneic blood SCT for children with Hurler’s syndrome: results from the German multicenter approach MPS-HCT 2005. Bone Marrow Transplant. 2009;43(5):375-381.
16. Weiner J, Lourie J. Practical Human Biology. Academic Press; 1981.
17. Živičnjak M, Narančić NS, Sziroviczka L, Franke D, Hrenović J, Bšof V. Gender-specific growth patterns for stature, sitting height and limbs length in Croatian children and youth (3 to 18 years of age). Coll Antropol. 2003;27:321-334.
18. Robert-Koch-Institut. Referenzenzentrale für anthropometrische Maßzahlen und Blutdruck aus der Studie zur Gesundheit von Kindern und Jugendlichen in Deutschland (KiGGS). 2nd ed. Beiträge zur Gesundheitsberichterstattung; 2013.
19. Różdyńska-Świątkowska A, Jurecka A, Cieslik J, Tylki-Szymańska A. Growth patterns in children with mucopolysaccharidosis I and II. *World J Pediatr*. 2015;11:226-231.

20. Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. *Nature*. 2007;446:1030-1037.

21. Viskochil D, Clarke LA, Bay I, Keenan H, Muenzer J, Guffon N. Growth patterns for untreated individuals with MPS I: report from the international MPS I registry. *Am J Med Genet Part A*. 2019;179(12):2425-2432.

22. Pavone P, Praticò AD, Rizzo R, et al. A clinical review on megalencephaly: a large brain as a possible sign of cerebral impairment. *Medicine*. 2017;96(26):e6814.

23. Kiely BT, Kohler JL, Coletti HY, Poe MD, Escolar ML. Early disease progression of hurler syndrome. *Orphanet J Rare Dis*. 2017;12(1):32.

24. Vellodi A, Young EP, Cooper A, et al. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. *Arch Dis Child*. 1997;76(2):92-99.

25. Weisstein JS, Delgado E, Steinbach LS, Hart K, Packman S. Musculoskeletal manifestations of hurler syndrome. *J Pediatr Orthop*. 2004;24(1):97-101.

26. Church H, Tylee K, Cooper A, et al. Biochemical monitoring after haemopoietic stem cell transplant for hurler syndrome (MPSIIH): implications for functional outcome after transplant in metabolic disease. *Bone Marrow Transplant*. 2007;39(4):207-210.

27. Polgreen LE, Tolar J, Plog M, et al. Growth and endocrine function in patients with hurler syndrome after hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2008;41:1005-1011.

28. Polgreen LE, Thomas W, Orchard PJ, Whitley CB, Miller BS. Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2years in children with hurler or hunter syndrome. *Mol Genet Metab*. 2014;112(2):101-106.

29. Cattoni A, Motta S, Masera N, Gasperini S, Rovelli A, Parini R. The use of recombinant human growth hormone in patients with Mucopolysaccharidosis and growth hormone deficiency: a case series. *Ital J Pediatr*. 2019;45:93.

30. Ranke MB, Schwarze CP, Dopfer R, et al. Late effects after stem cell transplantation (SCT) in children – growth and hormones. *Bone Marrow Transplant*. 2005;35(1):77-81.

31. Bakker B, Oostdijk W, Breuters D, Walenkamp MJE, Vossen JM, Wit JM. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. *Bone Marrow Transplant*. 2004;33(10):1049-1056.

32. Guffon N, Pettazzoni M, Panguaud N, et al. Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with hematopoietic stem cell transplantation (HSCT). *Orphanet J Rare Dis*. 2021;16:1-20.

33. Szopa A, Domagalska-Szopa M. Correlation between respiratory function and spine and thorax deformity in children with mild scoliosis. *Med (United States)*. 2017;96:1-5.

34. Kosch M, Schaefer RM. Störungen des Säuren-Basen-Haushalts. Diagnostik und klinisches Bild. *Deutsches Ärzteblatt*. 2005;102:1896-1899.

35. Taylor DB, Blaser SI, Burrows PE, Stringer DA, Clarke JT, Thorner P. Arteriopathy and coarctation of the abdominal aorta in children with mucopolysaccharidosis: imaging findings. *Am J Roentgenol*. 1991;157:819-823.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**Data S1** Supporting information

**How to cite this article:** Maier S, Zivicnjak M, Grigull L, et al. Predictors of growth patterns in children with mucopolysaccharidosis I after haematopoietic stem cell transplantation. *JIMD Reports*. 2022;63(4):371-378. doi:10.1002/jmd2.12291